Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children

被引:0
|
作者
Chiarenza, Decimo Silvio [1 ]
Verrina, Enrico Eugenio [1 ]
La Porta, Edoardo [1 ]
Caridi, Gianluca [1 ]
Ghiggeri, Gian Marco [1 ]
Mortari, Gabriele [1 ]
Lugani, Francesca [1 ]
Angeletti, Andrea [1 ]
Bigatti, Carolina [1 ]
机构
[1] IRCCS Ist Giannina Gaslini, Nephrol Dialysis & Transplantat Unit, I-16147 Genoa, Italy
关键词
IgA nephropathy; paediatric nephrology; biologics; rituximab; BAFF; APRIL; BAFF/APRIL inhibitors; sibeprenlimab; iptacopan; complement cascade; CONTROLLED-TRIAL; KIDNEY-TRANSPLANTATION; RITUXIMAB; CORTICOSTEROIDS; PROTEINURIA; COMPLEMENT; MANAGEMENT; EFFICACY; THERAPY; SAFETY;
D O I
10.3390/jcm13092465
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immunoglobulin A nephropathy represents the most prevalent cause of glomerulonephritis worldwide and may lead to renal failure in a relevant number of cases in both paediatric and adult subjects. Although their pathogenesis is still largely unclear, evidence of immune abnormalities provides the background for the use of immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and antiproliferative and alkylating agents. Unfortunately, these treatments fail to achieve a sustained remission in a significant percentage of affected patients and are burdened by significant toxicities. Recent developments of new biologics, including anti-BAFF/APRIL inhibitors and molecules targeting complement components, offered the opportunity to selectively target immune cell subsets or activation pathways, leading to more effective and safer hypothesis-driven treatments. However, studies testing new biologic agents in IgAN should also consider paediatric populations to address the unique needs of children and close the therapeutic gap between adult and paediatric care.
引用
收藏
页数:14
相关论文
共 28 条
  • [1] Incidence of Malignancies Spondyloarthritis Patients Treated with Biologics vs. Non-Biologics: A Systematic Review and Meta-analysis
    Alghamdi, Thekra Ali
    Zubani, Ohoud Mousa
    Alharbi, Shaima Humied
    Alahmadi, Walaa Faisal
    Alqarni, Sarah Abdullah
    Wajdi, Rahaf Fouad
    Alqahtani, Reem Mohammed
    Alzahrani, Atheer Musfer
    Alharbi, Lama Morshed
    Alaklouk, Suhailah Eid
    ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2021, 11 (01) : 1222 - 1227
  • [2] Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics
    Chiu, Ying-Ming
    Chen, Der-Yuan
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (02) : 207 - 228
  • [3] Systemic use of non-biologics in orofacial diseases: 2. Purine synthesis inhibitors
    Georgakopoulou, E. A.
    Scully, C.
    ORAL DISEASES, 2014, 20 (08) : 732 - 739
  • [4] Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features
    Cambier, Alexandra
    Rabant, Marion
    Peuchmaur, Michel
    Hertig, Alexandre
    Deschenes, Georges
    Couchoud, Cecile
    Kolko, Anne
    Salomon, Remi
    Hogan, Julien
    Robert, Thomas
    KIDNEY INTERNATIONAL REPORTS, 2018, 3 (04): : 916 - 925
  • [5] Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study
    Kostik, Mikhail
    Kalashnikova, Elvira
    Rinat, Raupov
    Isupova, Eugenia
    Gaidar, Ekaterina
    Soloviev, Anton A.
    Masalova, Vera
    Snegireva, Ludmila
    Kornishina, Tatyana
    Abramova, Natalia
    Suspitsin, Evgeny
    Sorokina, Lubov
    Kaneva, Maria
    Dubko, Margarita F.
    Lubimova, Natalia
    Kuchuinskaya, Ekaterina
    Kalashnikova, Olga
    Chasnyk, Vyacheslav
    BIOMEDICINES, 2023, 11 (05)
  • [6] Immunosuppressive therapy for IgA nephropathy in children (Review)
    Alladin, Areefa
    Hahn, Deirdre
    Hodson, Elisabeth M.
    Ravani, Pietro
    Pfister, Kenneth
    Quinn, Robert R.
    Samuel, Susan M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (06):
  • [7] Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors
    Jafarzadeh, Alireza
    Behrangi, Elham
    Khosravi, Mina
    Falakeh, Saba
    Amiri, Jasmine Khalilnejad
    Goodarzi, Azadeh
    INFLAMMOPHARMACOLOGY, 2025, : 1617 - 1672
  • [8] Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
    Trachtman, Howard
    Komers, Radko
    Inrig, Jula
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (06) : 571 - 576
  • [9] Non-immunosuppressive treatment for IgA nephropathy
    Reid, Sharon
    Cawthon, Peggy M.
    Craig, Jonathan C.
    Samuels, Joshua A.
    Molony, Donald A.
    Strippoli, Giovanni F. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (03):
  • [10] IgA nephropathy in children and in adults: two separate entities or the same disease?
    Coppo, Rosanna
    Robert, Thomas
    JOURNAL OF NEPHROLOGY, 2020, 33 (06) : 1219 - 1229